Luca Porcu

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2831612/publications.pdf

Version: 2024-02-01

331538 265120 2,123 42 97 21 citations h-index g-index papers 99 99 99 4442 citing authors docs citations times ranked all docs

#	Article	IF	CITATIONS
1	Spinocerebellar Ataxia Type 1: One-Year Longitudinal Study to Identify Clinical and MRI Measures of Disease Progression in Patients and Presymptomatic Carriers. Cerebellum, 2022, 21, 133-144.	1.4	13
2	A Definitive Prognostication System for Patients With Thoracic Malignancies Diagnosed With Coronavirus Disease 2019: An Update From the TERAVOLT Registry. Journal of Thoracic Oncology, 2022, 17, 661-674.	0.5	9
3	Association of Upfront Peptide Receptor Radionuclide Therapy With Progression-Free Survival Among Patients With Enteropancreatic Neuroendocrine Tumors. JAMA Network Open, 2022, 5, e220290.	2.8	21
4	Pharmacological and clinical monitoring in children with acute lymphoblastic leukemia treated with a biogeneric PEG― <scp>l</scp> â€asparaginase product. Pediatric Blood and Cancer, 2022, , e29753.	0.8	2
5	The p97â€Nploc4 ATPase complex plays a role in muscle atrophy during cancer and amyotrophic lateral sclerosis. Journal of Cachexia, Sarcopenia and Muscle, 2022, 13, 2225-2241.	2.9	7
6	Overall Survival in Metastatic Breast Cancer Patients in the Third Millennium: Results of the COSMO Study. Clinical Breast Cancer, 2021, 21, e489-e496.	1.1	11
7	Outcomes on safety and efficacy of left atrial appendage occlusion in end stage renal disease patients undergoing dialysis. Journal of Nephrology, 2021, 34, 63-73.	0.9	38
8	CDK 4/6 inhibitors mired in uncertainty in HR positive and HER2 negative early breast cancer. Breast, 2021, 55, 75-78.	0.9	11
9	Drug Holidays and Overall Survival of Patients with Metastatic Colorectal Cancer. Cancers, 2021, 13, 3504.	1.7	5
10	Proposal for a clinical and an echocardiographic score for prediction of left atrial thrombosis in atrial fibrillation patients undergoing early electrical cardioversion. International Journal of Clinical Practice, 2021, 75, e14706.	0.8	2
11	PEGylated recombinant human hyaluronidase (PEGPH20) pre-treatment improves intra-tumour distribution and efficacy of paclitaxel in preclinical models. Journal of Experimental and Clinical Cancer Research, 2021, 40, 286.	3.5	18
12	CXCL1-CXCR1/2 signaling is induced in human temporal lobe epilepsy and contributes to seizures in a murine model of acquired epilepsy. Neurobiology of Disease, 2021, 158, 105468.	2.1	15
13	Doxycycline rescues recognition memory and circadian motor rhythmicity but does not prevent terminal disease in fatal familial insomnia mice. Neurobiology of Disease, 2021, 158, 105455.	2.1	4
14	Lung metastasectomy for osteosarcoma in children, adolescents, and young adults: proof of permanent cure. Tumori, 2021, , 030089162110530.	0.6	5
15	Neuroinflammation, body temperature and behavioural changes in CD1 male mice undergoing acute restraint stress: An exploratory study. PLoS ONE, 2021, 16, e0259938.	1.1	3
16	Is There an Interplay between Immune Checkpoint Inhibitors, Thromboprophylactic Treatments and Thromboembolic Events? Mechanisms and Impact in Non-Small Cell Lung Cancer Patients. Cancers, 2020, 12, 67.	1.7	39
17	Determinants of choice in offering drug holidays during first-line therapy for metastatic colorectal cancer. Future Oncology, 2020, 16, 2645-2660.	1.1	1
18	Commentary: SARS-CoV-2 Transmission in Patients With Cancer at a Tertiary Care Hospital in Wuhan, China. Frontiers in Oncology, 2020, 10, 1223.	1.3	2

#	Article	IF	Citations
19	Effect of body mass index on response to neo-adjuvant therapy in HER2-positive breast cancer: an exploratory analysis of the NeoALTTO trial. Breast Cancer Research, 2020, 22, 115.	2.2	16
20	Metabolism and Immune Modulation in Patients with Solid Tumors: Systematic Review of Preclinical and Clinical Evidence. Cancers, 2020, 12, 1153.	1.7	4
21	Diagnostic and prognostic values of PBMC proteins in amyotrophic lateral sclerosis. Neurobiology of Disease, 2020, 139, 104815.	2.1	19
22	The Complex Balance between Analgesic Efficacy, Change of Dose and Safety Profile Over Time, in Cancer Patients Treated with Opioids: Providing the Clinicians with an Evaluation Tool. Journal of Clinical Medicine, 2020, 9, 502.	1.0	2
23	The sacral chordoma margin. European Journal of Surgical Oncology, 2020, 46, 1415-1422.	0.5	29
24	Progression of Cerebellar Atrophy in Spinocerebellar Ataxia Type 2 Gene Carriers: A Longitudinal MRI Study in Preclinical and Early Disease Stages. Frontiers in Neurology, 2020, 11, 616419.	1.1	16
25	A refinement approach in a mouse model of rehabilitation research. Analgesia strategy, reduction approach and infrared thermography in spinal cord injury. PLoS ONE, 2019, 14, e0224337.	1.1	15
26	RE: Presence of Circulating Tumor Cells in High-Risk Early Breast Cancer During Follow-Up and Prognosis. Journal of the National Cancer Institute, 2019, 111, 1232-1233.	3.0	0
27	Cognitive Syndromes and C9orf72 Mutation Are Not Related to Cerebellar Degeneration in Amyotrophic Lateral Sclerosis. Frontiers in Neuroscience, 2019, 13, 440.	1.4	10
28	Gadoxetate Disodium–Enhanced MR Cholangiography for Evaluation of Biliary-Enteric Anastomoses: Added Value Beyond Conventional T2-Weighted Images. American Journal of Roentgenology, 2019, 213, W123-W133.	1.0	4
29	Feasibility of Eribulin Mesylate in older patients with locally advanced or metastatic breast cancer: A post-hoc analysis of the ESEMPiO study. Journal of Geriatric Oncology, 2019, 10, 990-993.	0.5	3
30	Prognostic nutritional index as a prognostic marker in glioblastoma: Data from a cohort of 282 Italian patients. Journal of the Neurological Sciences, 2019, 400, 175-179.	0.3	16
31	Oral maintenance metronomic vinorelbine versus best supportive care in advanced non-small-cell lung cancer after platinum-based chemotherapy: The MA.NI.LA. multicenter, randomized, controlled, phase II trial. Lung Cancer, 2019, 132, 17-23.	0.9	12
32	HER2 Positivity Predicts Unresponsiveness to EGFR-Targeted Treatment in Metastatic Colorectal Cancer. Oncologist, 2019, 24, 1395-1402.	1.9	95
33	Combination of PPARÎ ³ Agonist Pioglitazone and Trabectedin Induce Adipocyte Differentiation to Overcome Trabectedin Resistance in Myxoid Liposarcomas. Clinical Cancer Research, 2019, 25, 7565-7575.	3.2	15
34	Antibody–Fc/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Non–small Cell Lung Cancer Subsequent to PD-1/PD-L1 Blockade. Clinical Cancer Research, 2019, 25, 989-999.	3.2	315
35	Eribulin in the treatment of advanced breast cancer: real-world scenario from 39 Italian centers – ESEMPiO study. Future Oncology, 2019, 15, 33-44.	1.1	18
36	Interhemispherical Anatomical Disconnection in Disorders of Consciousness Patients. Journal of Neurotrauma, 2019, 36, 1535-1543.	1.7	9

#	Article	IF	CITATIONS
37	Molecular isoforms of high-mobility group box 1 are mechanistic biomarkers for epilepsy. Journal of Clinical Investigation, 2019, 129, 2166-2166.	3.9	11
38	Title is missing!., 2019, 14, e0224337.		0
39	Title is missing!. , 2019, 14, e0224337.		0
40	Title is missing!. , 2019, 14, e0224337.		0
41	Title is missing!. , 2019, 14, e0224337.		0
42	Antiepileptic treatment and survival in newly diagnosed glioblastoma patients: Retrospective multicentre study in 285 Italian patients. Journal of the Neurological Sciences, 2018, 390, 14-19.	0.3	7
43	Implant success and safety of left atrial appendage occlusion in end stage renal disease patients: Peri-procedural outcomes from an Italian dialysis population. International Journal of Cardiology, 2018, 262, 38-42.	0.8	22
44	Inhibition of monoacylglycerol lipase terminates diazepamâ€resistant status epilepticus in mice and its effects are potentiated by a ketogenic diet. Epilepsia, 2018, 59, 79-91.	2.6	37
45	Assessment of proportional hazard assumption in aggregate data: a systematic review on statistical methodology in clinical trials using time-to-event endpoint. British Journal of Cancer, 2018, 119, 1456-1463.	2.9	43
46	n-3 Docosapentaenoic acid-derived protectin D1 promotes resolution of neuroinflammation and arrests epileptogenesis. Brain, 2018, 141, 3130-3143.	3.7	55
47	Soluble stromaâ€related biomarkers of pancreaticÂcancer. EMBO Molecular Medicine, 2018, 10, .	3.3	56
48	Clinicopathological characteristics and HER2 status in metastatic colorectal cancer patients: Results of a diagnostic model development study Journal of Clinical Oncology, 2018, 36, 581-581.	0.8	3
49	A phase 2 study of cabozantinib as first-line treatment in collecting ducts renal cell carcinoma: The BONSAI trial Journal of Clinical Oncology, 2018, 36, TPS709-TPS709.	0.8	O
50	A randomized phase II trial of maintenance oral metronomic vinorelbine versus close observation in advanced non-small cell lung cancer (NSCLC) following platinum-based chemotherapy: MA.NI.LA. trial Journal of Clinical Oncology, 2018, 36, e21101-e21101.	0.8	0
51	Antitumour activity of trabectedin in myelodysplastic/myeloproliferative neoplasms. British Journal of Cancer, 2017, 116, 335-343.	2.9	20
52	Complete remission in metastatic breast cancer: expecting the unexpectedâ€"results of a cross-sectional study. Breast Cancer, 2017, 24, 635-641.	1.3	5
53	Pharmacodynamic effects in the cerebrospinal fluid of rats after intravenous administration of different asparaginase formulations. Cancer Chemotherapy and Pharmacology, 2017, 79, 1267-1271.	1.1	5
54	Efficacy and safety of eribulin in taxane-refractory patients in the â€real world'. Future Oncology, 2017, 13, 971-978.	1.1	13

#	Article	IF	CITATIONS
55	Sudden Death in End Stage Renal Disease: Comparing Hemodialysis versus Peritoneal Dialysis. Blood Purification, 2017, 44, 77-88.	0.9	22
56	Outcome of Patients with Renal Cell Carcinoma and Multiple Glandular Metastases Treated with Targeted Agents. Oncology, 2017, 92, 269-275.	0.9	5
57	Autologous fat tissue grafting improves pulmonary healing after laser metastasectomy. European Journal of Surgical Oncology, 2017, 43, 2315-2323.	0.5	5
58	Ascites interferes with the activity of lurbinectedin and trabectedin: Potential role of their binding to alpha 1-acid glycoprotein. Biochemical Pharmacology, 2017, 144, 52-62.	2.0	11
59	Does Dose Modification Affect Efficacy of First-Line Pazopanib in Metastatic Renal Cell Carcinoma?. Drugs in R and D, 2017, 17, 461-467.	1.1	5
60	Efficacy and Safety of Bevacizumab Combined With Fluoropyrimidine Monotherapy for Unfit or Older Patients With Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis. Clinical Colorectal Cancer, 2017, 16, e61-e72.	1.0	18
61	Neoadjuvant Chemotherapy Exerts Selection Pressure Towards Luminal Phenotype Breast Cancer. Breast Care, 2017, 12, 391-394.	0.8	9
62	Efficacy and Safety of Vinorelbine-Capecitabine Oral Metronomic Combination in Elderly Metastatic Breast Cancer Patients: VICTOR-1 Study. Tumori, 2017, 103, e4-e8.	0.6	17
63	Molecular isoforms of high-mobility group box 1 are mechanistic biomarkers for epilepsy. Journal of Clinical Investigation, 2017, 127, 2118-2132.	3.9	90
64	Does dose modification affect efficacy of first-line pazopanib in metastatic renal cell carcinoma?. Journal of Clinical Oncology, 2017, 35, 512-512.	0.8	1
65	Patient-derived ovarian cancer xenografts re-growing after a cisplatinum treatment are less responsive to a second drug re-challenge: a new experimental setting to study response to therapy. Oncotarget, 2017, 8, 7441-7451.	0.8	23
66	Abstract 2981: Identification of circulating stroma-related biomarkers for pancreatic ductal adenocarcinoma. , 2017, , .		0
67	Sacral Chordoma: Long-term Outcome of a Large Series of Patients Surgically Treated at Two Reference Centers. Spine, 2016, 41, 1049-1057.	1.0	74
68	Multimodal study of defaultâ€mode network integrity in disorders of consciousness. Annals of Neurology, 2016, 79, 841-853.	2.8	67
69	Radiological imaging markers predicting clinical outcome in patients with metastatic colorectal carcinoma treated with regorafenib: post hoc analysis of the CORRECT phase III trial (RadioCORRECT) Tj ETQq1	1 02 7.6 431	4 r gB T /Over
70	The Third Italian Consensus Conference for Malignant Pleural Mesothelioma: State of the art and recommendations. Critical Reviews in Oncology/Hematology, 2016, 104, 9-20.	2.0	87
71	Cognitive deficits and brain myo-Inositol are early biomarkers of epileptogenesis in a rat model of epilepsy. Neurobiology of Disease, 2016, 93, 146-155.	2.1	54
72	Non-clinical factors influencing pain intensity in cancer patients: Socio-cultural–economic status, awareness of disease and the relation with the oncologist. European Journal of Internal Medicine, 2016, 33, e18-e19.	1.0	4

#	Article	IF	CITATIONS
73	Phase II trial of salvage therapy with trabectedin in metastatic pancreatic adenocarcinoma. Cancer Chemotherapy and Pharmacology, 2016, 77, 477-484.	1.1	13
74	Predictors of long-term response to abiraterone in patients with metastastic castration-resistant prostate cancer: a retrospective cohort study. Oncotarget, 2016, 7, 40085-40094.	0.8	17
75	Efficacy and safety of bevacizumab combined with fluoropyrimidine monotherapy in unfit or older metastatic colorectal cancer patients: A systematic review and pooled-analysis Journal of Clinical Oncology, 2016, 34, 705-705.	0.8	0
76	Surgery and Survival of Patients with Diagnosis of Malignant Pleural Mesothelioma: In Response. Journal of Thoracic Oncology, 2015, 10, e93-e94.	0.5	0
77	Oral prevalence and clearance of oncogenic human papilloma virus in a rehabilitation community for substance abusers in Italy: a case of behavioral correction?. Journal of Oral Pathology and Medicine, 2015, 44, 728-733.	1.4	3
78	Sites of disease as predictors of outcome in metastatic renal cell carcinoma patients treated with first-line sunitinib or sorafenib. Therapeutic Advances in Urology, 2015, 7, 59-68.	0.9	2
79	Disease progression pattern in metastatic breast cancer patients treated with anti-HER2 therapies. Clinical and Translational Oncology, 2015, 17, 530-538.	1.2	2
80	Mortality, sudden death and indication for cardioverter defibrillator implantation in a dialysis population. International Journal of Cardiology, 2015, 186, 170-177.	0.8	10
81	Cediranib combined with chemotherapy reduces tumor dissemination and prolongs the survival of mice bearing patient-derived ovarian cancer xenografts with different responsiveness to cisplatin. Clinical and Experimental Metastasis, 2015, 32, 647-658.	1.7	17
82	A broad Italian experience with eribulin mesylate in metastatic breast cancer patients: The ESEMPiO study Journal of Clinical Oncology, 2015, 33, e11539-e11539.	0.8	3
83	Does Surgery Improve Survival of Patients with Malignant Pleural Mesothelioma?: A Multicenter Retrospective Analysis of 1365 Consecutive Patients. Journal of Thoracic Oncology, 2014, 9, 390-396.	0.5	123
84	Targeted therapies in advanced renal cell carcinoma: the role of metastatic sites as a prognostic factor. Future Oncology, 2014, 10, 1361-1372.	1.1	9
85	Use of adjuvant chemotherapy (CT) and radiotherapy (RT) in incompletely resected (R1) early stage Non-Small Cell Lung Cancer (NSCLC): A European survey conducted by the European Society for Medical Oncology (ESMO) Young Oncologists Committee. Lung Cancer, 2014, 85, 74-80.	0.9	12
86	The impact of personalized medicine on survival: Comparisons of results in metastatic breast, colorectal and non-small-cell lung cancers. Cancer Treatment Reviews, 2014, 40, 485-494.	3.4	21
87	Clinical Outcome of HER2-positive Breast Cancer Patients after Failure on Adjuvant Trastuzumab: The Potential of the Time to Relapse. Clinical Oncology, 2014, 26, 174.	0.6	2
88	Thulium laser versus staplers for anatomic pulmonary resections with incomplete fissures: negative results of a randomized trial. Tumori, 2014, 100, 259-64.	0.6	6
89	Liver metastases as predictors of outcome in renal cell carcinoma (RCC) patients (pts) treated with first-line sunitinib (SU) and sorafenib (SO) Journal of Clinical Oncology, 2014, 32, 536-536.	0.8	1
90	HER2-positive (HER2+) metastatic breast cancer (MBC) presentation and patterns of progression Journal of Clinical Oncology, 2014, 32, e11591-e11591.	0.8	0

#	ARTICLE	IF	CITATION
91	The natural history of HER2-overexpressing (HER2+) metastatic breast cancer (MBC) treated with trastuzumab (T): Practical points to consider in developing treatment strategies Journal of Clinical Oncology, 2014, 32, e11565-e11565.	0.8	0
92	Efficacy of trastuzumab in unselected patients with HER2-positive metastatic breast cancer: a retrospective analysis. Tumori, 2014, 100, 426-31.	0.6	0
93	Comparison of <i>in vitro</i> and <i>in vivo</i> biological effects of trabectedin, lurbinectedin (PMO1183) and Zalypsis® (PMO0104). International Journal of Cancer, 2013, 133, 2024-2033.	2.3	54
94	Resistance to platinum-based chemotherapy is associated with epithelial to mesenchymal transition in epithelial ovarian cancer. European Journal of Cancer, 2013, 49, 520-530.	1.3	141
95	DNA-damage response gene polymorphisms and therapeutic outcomes in ovarian cancer. Pharmacogenomics Journal, 2013, 13, 159-172.	0.9	16
96	Prognostic factors for survival in patients with metastatic renal cell carcinoma treated with targeted therapies. British Journal of Cancer, 2012, 107, 1227-1232.	2.9	18
97	The Zinc Finger Gene <i>ZIC2</i> Has Features of an Oncogene and Its Overexpression Correlates Strongly with the Clinical Course of Epithelial Ovarian Cancer. Clinical Cancer Research, 2012, 18, 4313-4324.	3.2	53